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Abstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein
(LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of
triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was
to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients
with coronary artery disease (CAD).
Methods: Serum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101
patients with CAD who were not receiving lipid-lowering therapy.
Results: Serum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05);
small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed
that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense
LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).
Conclusions: Serum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized
LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins
plays a role in establishing the atherosclerotic status of patients.
Trial registration: UMIN Clinical Trials Registry, UMIN ID: C000000311.
Keywords: Low-density lipoprotein (LDL) cholesterol, Proprotein convertase subtilisin/kexin type 9 (PCSK9),
Lipoprotein(a), Oxidized LDL, Small, dense LDL
Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a
key regulator of serum low-density lipoprotein (LDL)
cholesterol levels [1, 2]. PCSK9, which is secreted by the
liver into the circulation, binds the hepatic LDL receptors
(LDLRs), causing their subsequent degradation [3, 4].
Although the mechanism underlying PCSK9-mediated
degradation of LDLR is extremely complex, it bind to
LDLR subsequently targeting them for intracellular
destruction within the hepatocyte, resulting in an increase
in LDL cholesterol levels [5–7]. Therefore, PCSK9
antibodies represent attractive candidates for lowering
LDL cholesterol levels.
Elevated levels of lipoprotein(a) [Lp(a)]; small, dense
LDL; and oxidized LDL are recognized as risk factors for
atherosclerotic cardiovascular disease (ASCVD) [8–11].
The levels of both small, dense LDL and oxidized LDL
may be lowered by statin therapy [12, 13]; however, the
availability of pharmacological agents for lowering Lp(a)
levels is limited. Therefore, Lp(a) levels represent a
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residual risk factor for cardiovascular events in this
statin era [14]. Although monoclonal antibodies against
PCSK9 have been reported to lower Lp(a) levels [15],
the mechanisms underlying this effect are poorly
understood.
Several demographic and metabolic parameters appear
to correlate with serum PCSK9 levels, including plasma
LDL cholesterol, high-density lipoprotein (HDL) cho-
lesterol, triglycerides, apolipoprotein B (apoB), insulin,
glucose, smoking, and body mass index [16–18]. In
addition, circulating PCSK9 strongly correlates with
intermediate-density lipoprotein particles, suggesting a
link between PCSK9 and triglyceride-rich lipoprotein
metabolism [19]. However, to our knowledge, correla-
tions between serum levels of PCSK9 and small, dense
LDL or oxidized LDL have not been evaluated to date.
In addition, few studies concerning the association of
PCSK9 with Lp(a) have been reported. Therefore, the aim
of this study was to investigate correlations between
serum levels of PCSK9 and apoB-containing atherogenic
lipoproteins such as Lp(a); small, dense LDL; and oxidized
LDL in patients with coronary artery disease (CAD).
Methods
Patients and study design
The present study is a post-hoc analysis of the Treatment
With Statin on Atheroma Regression Evaluated by Intra-
vascular Ultrasound With Virtual Histology (TRUTH)
study, which was a prospective, open-labeled, randomized,
multicenter trial performed at 11 Japanese centers [20]. In
brief, 164 patients with angina pectoris, who were not re-
ceiving any lipid-lowering therapy, were randomly treated
with either 4 mg/day of pitavastatin or 20 mg/day of
pravastatin.
The patients included in the TRUTH study were
considered for the present study if an adequate serum
volume, before statin treatment, was available in frozen
samples from these patients; a total of 101 patients met
this inclusion criterion.
This study was conducted in accordance with the Dec-
laration of Helsinki and with the approval of the ethical
committees of Yokohama Sakae Kyosai Hospital. Each
patient enrolled in the present study provided written
informed consent.
Laboratory analysis
Serum levels of total cholesterol, LDL cholesterol, HDL
cholesterol, and triglycerides were measured using stand-
ard enzymatic methods (AU2700; Beckman Coulter, CA,
USA) and commercial enzymatic kits (Kyowa Medex,
Tokyo, Japan). Serum levels of two forms of PCSK9, ma-
ture (hetero-dimer) and furin-cleaved, were measured at a
central laboratory (BML, Kawagoe, Japan) using sandwich
enzyme-linked immunosorbent assays (ELISAs) [21]. It
has been reported that furin-cleaved PCSK9 has no activ-
ity to regulate LDLR and serum LDL cholesterol or less
activity than mature PCSK9 [21]. Serum oxidized LDL
levels were measured by an enzyme immunoassay [22].
Serum Lp(a) levels were measured by a latex agglutination
turbidimetric immunoassay using the commercially avail-
able Lp(a)-LATEX (Sekisui Medical Co., Ltd., Tokyo) with
an autoanalyzer (JCA-BM8040; JEOL Ltd., Tokyo). Serum
small, dense LDL levels were measured by a homogeneous
assay (Denka Seiken Co., Ltd., Tokyo) [23].
Statistical analysis
Statistical analysis was performed using StatView, ver-
sion 5.0 (SAS Institute, Cary, North Carolina). The re-
sults are expressed as means ± SD or median values
(range). Univariate and multivariate linear regression
analyses were performed to assess the correlations be-
tween serum levels of apoB-containing atherogenic lipo-
protein and biochemical parameters, including nominal
variables (gender, hypertension, diabetes mellitus, and
smoking) and numerical variables (age, body mass index,
total cholesterol, LDL cholesterol, triglycerides, HDL
cholesterol, apoA1, apoB, hetero-dimer PCSK9, and
furin-cleaved PCSK9). The variables with a p value < 0.1
on univariate analysis were entered into multivariate
models. Statistical significance was set at p < 0.05.
Results
The baseline characteristics of the subjects are listed in
Table 1. Eighty-four patients were of male gender with a
mean age of 67 ± 10 years. Forty-five of the patients were
additionally diabetic.
Serum levels of lipid, PCSK9, and apoB-containing li-
poproteins are shown in Table 2. The mean levels of
LDL cholesterol and apoB were 129 ± 31 mg/dl and 103
± 24 mg/dl, respectively. Serum hetero-dimer PCSK9
levels were 145 ± 60 ng/ml. Median levels of Lp(a) were
16 mg/dl, and mean levels of small, dense LDL and
Table 1 Baseline characteristics of subjects
Age (years) 67 ± 10
Male (%) 84 (83 %)
Body mass index (kg/m2) 24.3 ± 3.4
Hypertension (%) 66 (65 %)
Diabetes (%) 45 (45 %)
Family history of CAD (%) 10 (10 %)
Smoking (%) 23 (23 %)
Treated with ACE inhibitors or ARBs (%) 55 (54 %)
Treated with CCBs (%) 54 (53 %)
Treated with beta-blockers (%) 10 (10 %)
Data are expressed as the means ± SD or number (%)
ACE angiotensin-converting enzyme, ARBs angiotensin-receptor blockers,
CCBs calcium channel blockers
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oxidized LDL were 25.8 ± 13.9 mg/dl and 11.8 ± 8.5 U/ml,
respectively.
Correlations between levels of apoB-containing lipopro-
teins and biochemical parameters are shown in Table 3.
Univariate analysis indicated that total cholesterol, apoB,
and hetero-dimer PCSK9 levels (Fig. 1) positively corre-
lated with serum levels of Lp(a). Multivariate regression
analysis showed that serum apoB and PCSK9 levels were
significant positive predictors of Lp(a) levels. In addition,
total cholesterol, LDL cholesterol, triglycerides, apoB, and
hetero-dimer PCSK9 levels (Fig. 2) positively correlated
with serum small, dense LDL levels. Multivariate regres-
sion analysis showed that apoB and hetero-dimer PCSK9
levels were significant positive predictors of small, dense
LDL levels. Moreover, univariate and multivariate analyses
showed that serum hetero-dimer PCSK9 levels positively
correlated with serum oxidized LDL levels (Fig. 3). There-
fore, weak, but significant, positive correlations were ob-
served between serum levels of hetero-dimer PCSK9 and
apoB-containing lipoproteins such as Lp(a); small, dense
LDL; and oxidized LDL.
Discussion
The major findings of the present study are as follows:
first, serum hetero-dimer PCSK9 levels were positively
correlated with serum Lp(a) levels. Second, significant
positive correlations were observed between serum
levels of hetero-dimer PCSK9 and small, dense LDL or
oxidized LDL. Finally, the serum hetero-dimer PCSK9
level was a significant predictor of serum levels of apoB-
containing atherogenic lipoproteins.
Lp(a) is a LDL-like particle synthesized by the liver, that
consists of an apoB100 molecule linked to a very large
glycoprotein known as the apolipoprotein(a) [8, 24]. The
biological role of Lp(a) is uncertain; however, elevated
levels of Lp(a) have been identified as an independent risk
factor for ASCVD [8, 9]. Several recent clinical trials have
reported that PCSK9 antibodies represent promising novel
candidate drugs for lowering the levels of both LDL chol-
esterol and Lp(a) [25–27]. However, the mechanism by
which PCSK9 inhibitors reduce Lp(a) levels remains un-
clear. Serum Lp(a) levels in familial hypercholesterolemia
with LDLR mutations have been shown to be elevated,
suggesting that Lp(a) is catabolized via the LDLR pathway
Table 2 Serum levels of lipids, PCSK9, and atherogenic
lipoprotein
Total cholesterol (mg/dl) 202 ± 34
LDL cholesterol (mg/dl) 129 ± 31
Triglycerides (mg/dl) 114 (36–573)
HDL cholesterol (mg/dl) 47 ± 11
Apolipoprotein A1 (mg/dl) 118 ± 20
Apolipoprotein B (mg/dl) 103 ± 24
Hetero-dimer PCSK9 (ng/ml) 145 ± 60
Furin-cleaved PCSK9 (ng/ml) 47 ± 32
Lipoprotein(a) (mg/dl) 16 (1–47)
Small, dense LDL (mg/dl) 25.8 ± 13.9
Oxidized LDL (U/ml) 11.8 ± 8.5
Data are expressed as means ± SD or median (range)
LDL low-density lipoprotein, HDL high-density lipoprotein, PCSK9 proprotein
convertase subtilisin/kexin type 9
Table 3 Correlations between biochemical parameters and atherogenic lipoproteins levels
Lipoprotein(a) Small, dense LDL Oxidized LDL
r p value β p value r p value β p value r p value β p value
Age 0.129 0.2 −0.289 0.003 −0.056 0.41 −0.017 0.87
Sex −0.030 0.77 −0.072 0.48 0.084 0.42
Body mass index −0.180 0.08 −0.317 0.0009 0.233 0.02 0.028 0.68 −0.066 0.53
Hypertension 0.060 0.55 −0.103 0.31 0.085 0.41
Diabetes −0.107 0.29 0.160 0.11 −0.100 0.33
Smoking −0.189 0.06 −0.273 0.004 −0.004 0.97 −0.073 0.48
Total cholesterol 0.196 0.05 −0.241 0.24 0.711 <0.0001 0.209 0.19 0.080 0.44
LDL cholesterol 0.144 0.15 0.611 <0.0001 −0.269 0.22 0.039 0.71
Triglycerides 0.029 0.77 0.585 <0.0001 0.150 0.15 0.053 0.61
HDL cholesterol 0.129 0.2 −0.109 0.28 0.069 0.5
Apolipoprotein A1 0.056 0.58 0.022 0.82 0.047 0.65
Apolipoprotein B 0.260 0.009 0.573 0.007 0.758 <0.0001 0.683 0.005 0.112 0.28
Hetero-dimer PCSK9 0.195 0.05 0.235 0.01 0.336 0.0006 0.143 0.03 0.268 0.008 0.268 0.008
Furin-cleaved PCSK9 0.063 0.53 0.234 0.02 0.026 0.8
Male gender, hypertension, diabetes, and smoking were assigned a value of 1. Female gender, normotension, non-diabetes, and non-smoking were assigned a
value of 0
LDL low-density lipoprotein, HDL high-density lipoprotein, PCSK9 proprotein convertase subtilisin/kexin type 9
Nozue et al. Lipids in Health and Disease  (2016) 15:165 Page 3 of 7
[28]; however, statins, whose main mechanism of action
involves the upregulation of LDLR, are unable to reduce
Lp(a) levels effectively [29]. In addition, Tada et al. recently
reported that serum Lp(a) was elevated in patients with
familial hypercholesterolemia caused by PCSK9 gain-of-
function mutations to the same level as that in familial
hypercholesterolemia caused by LDLR mutations [30].
This suggests that the LDLR plays an important role in
Lp(a) catabolism. Furthermore, Romagnuolo et al.
reported that Lp(a) catabolism is regulated by PCSK9 via
LDLR in HEPG2 cells and primary human fibroblasts
[31]. However, a previous study reported that apoB in
Lp(a) does not interact with LDLR, suggesting that LDLR
does not play a role in Lp(a) kinetics [24].
In order to understand the mechanism by which
PCSK9 antibodies reduce Lp(a) levels, elucidation of the
correlation between serum levels of PCSK9 and Lp(a) is
required. A recent study by Nekaies et al. reported that
plasma PCSK9 levels correlated positively with Lp(a)
concentrations [32]. However, Yang et al. reported that
plasma PCSK9 levels are not associated with Lp(a) levels
[33]. Therefore, the correlation between plasma PCSK9
and Lp(a) levels remains controversial. Significant posi-
tive correlations were observed between serum levels of
PCSK9 and Lp(a) in the present study; furthermore,
serum apoB levels were additionally found to be posi-
tively correlated with serum Lp(a) levels. Our findings
suggest that both PCSK9 and apoB interact with Lp(a).
Variations in terms of correlation between PCSK9 and
Lp(a) observed between patients may be attributed to
differences in race, as both PCSK9 and Lp(a) levels vary
considerably by race and other factors [18, 24, 34].
Small, dense LDL has been proposed to enhance athero-
genicity owing to its higher rate of penetration into the ar-
terial wall, prolonged plasma half-time, and lower affinity
of LDLR [35]. Numerous previous studies have examined
the association of small, dense LDL with traditional car-
diovascular risk factors [36, 37]. In agreement with these
previous reports, univariate analysis performed in the
present study indicated that serum small, dense LDL
levels were correlated with the concentration of total
Fig. 1 Correlation between serum levels of hetero-dimer PCSK9 and
Lp(a). A significant positive correlation was observed between serum
levels of hetero-dimer PCSK9 and Lp(a)
Fig. 2 Correlation between serum levels of hetero-dimer PCSK9 and
small, dense LDL. A significant positive correlation was observed
between serum levels of hetero-dimer PCSK9 and small, dense LDL
Fig. 3 Correlation between serum levels of hetero-dimer PCSK9 and
oxidized LDL. A significant positive correlation was observed between
serum levels of hetero-dimer PCSK9 and oxidized LDL
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cholesterol, LDL cholesterol, triglycerides, and apoB.
However, multivariate regression analysis showed that
apoB and PCSK9 levels were significant predictors of
small, dense LDL levels. Recently, Kwakernaak et al. found
no association between plasma PCSK9 levels and small,
dense LDL in healthy subjects [19]. However, Zhang et al.
reported that plasma PCSK9 levels are positively associ-
ated with plasma small, dense LDL in patients with CAD;
however, this association was not observed in subjects
without CAD [38]. Therefore, the levels of plasma PCSK9
and small, dense LDL may be correlated in atherosclerotic
patients. Although the exact mechanisms underlying the
positive correlation between PCSK9 and small, dense LDL
levels remain to be elucidated, PCSK9-induced LDLR deg-
radation, which results in lower LDLR levels, potentially
affects LDL subfractions, as characterized by the increased
levels of small, dense LDL.
Oxidized LDL is also highly atherogenic and elevated
levels of oxidized LDL recognized as a risk factor for
ASCVD [11, 39]. Oxidized LDL levels have been re-
ported to be positively correlated with PCSK9 concen-
tration [40]. Consistent with this finding, we observed a
positive correlation between serum levels of PCSK9 and
oxidized LDL. This observation may be attributed to the
involvement of PCSK9 in inflammatory and oxidative
processes [41, 42]. In addition, inhibition of PCSK9
suppresses the inflammatory response induced by oxi-
dized LDL in macrophages [43]. Further, circulatory
PCSK9 is not only present in its free form, but is
additionally complexed with apoB-containing lipoproteins
[44]. Our findings indicate that serum PCSK9 levels
positively correlated with apoB-containing lipoproteins
such as Lp(a); small, dense LDL; and oxidized LDL.
Several recent clinical trials have reported that PCSK9
antibodies reduce Lp(a) levels [25–27]. However, there
are no reports on the effects of PCSK9 antibodies on
small, dense LDL or oxidized LDL. In view of the finding
that PCSK9 antibodies reduced LDL cholesterol levels
and particle numbers [45], we speculate that PCSK9
antibodies reduce small, dense LDL as well as oxidized
LDL levels.
Plasma PCSK9 levels have been reported to be asso-
ciated with severity of CAD as well as future risk of
cardiovascular disease [46, 47]. In addition, plasma
PCSK9 levels were significantly higher in patients with
peripheral artery disease, especially those with exten-
sive, severe, and complicated forms of the condition
[40], suggesting that PCSK9 functions as a proathero-
genic molecule [48]. Furthermore, PCSK9 is expressed
in atherosclerotic plaques [41, 49]. Therefore, PCSK9-
targeting strategies may represent potential thera-
peutic options for the treatment of ASCVD, whose
mechanisms of action go beyond the reduction of LDL
cholesterol.
The present study has several limitations in that it
provides a post-hoc analysis of the results of the
TRUTH trial. Plasma PCSK9 levels have been re-
ported to be elevated in patients with acute myocar-
dial infarction and associated with severity of CAD
[46, 50]. In the present study, all subjects were
patients with CAD; no control group was studied. In
addition, serum PCSK9 levels were measured using
frozen samples. Further, we did not evaluate the
LDLR and PCSK9 expression in hepatocytes. Finally,
the small number of patients included in the study
resulted in low statistical power.
Despite these limitations, to the best of our knowledge,
this is the first study to examine the correlations be-
tween serum levels of PCSK9 and apoB-containing
atherogenic lipoproteins. A prospective study with a
larger number of patients is required to confirm our
conclusions.
Conclusions
Serum PCSK9 levels were positively correlated with
serum levels of Lp(a); small, dense LDL; and oxidized
LDL in patients with CAD. This suggests that serum
PCSK9 levels are correlated with those of apoB-
containing lipoproteins in atherosclerotic patients.
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